Durlobactam

Synonym(s): ETX-2514  |  ETX2514

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Details of activity:	DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and weakly inhibits penicillin binding protein 2 in Enterobacteriaceae
Combined with other compounds:	Yes
Description:	Synthetic compound. In clinical development in fixed combination with Sulbactam against Acinetobacter infections.
Institute where first reported:	Entasis Therapeutics, Innoviva
Year first mentioned:	2017
Highest developmental phase:	Phase 3 (NCT03894046)
Development status:	Active (as of 2022)

Chemical structure(s):
Canonical SMILES:	CC1=C[C@@H]2CN([C@@H]1C(=O)N)C(=O)N2OS(=O)(=O)O
Isomeric SMILES:	CC1=C[C@@H]2CN([C@@H]1C(=O)N)C(=O)N2OS(=O)(=O)O
InChI:	InChI=1S/C8H11N3O6S/c1-4-2-5-3-10(6(4)7(9)12)8(13)11(5)17-18(14,15)16/h2,5-6H,3H2,1H3,(H2,9,12)(H,14,15,16)/t5-,6+/m1/s1
InChI Key:	BISPBXFUKNXOQY-RITPCOANSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/89851852

External links:
Guide to Pharmacology:	durlobactam
Main Source:	https://pubmed.ncbi.nlm.nih.gov/28835096/